Table 2.
Urine biomarker levels of patients with DV and controls.
| Urine biomarkers@ | DV group (n = 43) |
Control group (n = 25) |
P value |
|---|---|---|---|
| 8-OHdG | 32.09 ± 19.72 (0) | 17.01 ± 14.59 (0) | 0.002 |
| 8-isoprostane | 12.94 ± 14.88 (1) | 15.32 ± 15.34 (1) | 0.098 |
| TAC | 607.28 ± 418.15 (2) | 1006.32 ± 984.39 (0) | 0.144 |
| IL-1β | 1.19 ± 1.43 (1) | 0.48 ± 0.20 (1) | < 0.001 |
| IL-2* | 0.26 ± 0.21 (0) | 0.73 ± 0.18 (0) | < 0.001 |
| IL-6 | 2.21 ± 5.28 (2) | 0.74 ± 0.35 (1) | 0.729 |
| IL-8 | 31.83 ± 65.21 (1) | 12.68 ± 25.3 (0) | 0.020 |
| TNFα* | 1.23 ± 0.33 (2) | 0.69 ± 0.19 (0) | < 0.001 |
| NGF* | 0.22 ± 0.05 (1) | 0.25 ± 0.06 (0) | 0.033 |
| BDNF | 0.64 ± 0.15 (0) | 0.58 ± 0.15 (0) | 0.030 |
DV Dysfunctional voiding, 8-OHdG 8-hydroxy-2-deoxyguanosine, TAC Total antioxidant capacity, TNFα Tumor necrosis factor alpha, NGF Nerve growth factor, BDNF Brain-derived neurotrophic factor.
(): number of outliers.
*: Mean values of the study group that were below the minimum detectable concentrations as per the assay manufacturer.
@: units: all pg/mL, except for ng/mL in 8-OHdG and mmol/μL in TAC.